InspireMD Announces Third Quarter 2020 Financial Results
ET
- ET
TEL AVIV, Israel, Nov. 09, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR)(Inspire or the Company), developer of the CGuard Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced financial and operating results for the third quarter ended September 30, 2020. - Third Quarter 2020 and recent highlights:
The U.S. Food and Drug Administration (FDA) granted InspireMD approval of its Investigational Device Exemption (IDE) application to initiate a pivotal study of CGuard EPS. - Financial Results for the Third Quarter and Nine Months ended September 30, 2020
For the three months ended September 30, 2020, revenue increased by $41,000, or 4.4%, to $980,000, from $939,000 during the three months ended September 30, 2019. - Management will host a conference call at 8:30AM ET today, November 9, 2020, to review financial results and provide an update on corporate developments.